Market revenue in 2024 | USD 34,660.4 million |
Market revenue in 2030 | USD 48,616.9 million |
Growth rate | 5.8% (CAGR from 2025 to 2030) |
Largest segment | Conventional drugs (small molecules) |
Fastest growing segment | Biologics & Biosimilars (Large Molecules) |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Biologics & Biosimilars (Large Molecules), Conventional Drugs (Small Molecules) |
Key market players worldwide | Merck & Co Inc, Roche Holding AG, Novartis AG ADR, AbbVie Inc, Johnson & Johnson, Pfizer Inc, Bristol-Myers Squibb Co, Sanofi SA, GSK PLC, Takeda Pharmaceutical Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pharmaceutical market will help companies and investors design strategic landscapes.
Conventional drugs (small molecules) was the largest segment with a revenue share of 57.4% in 2024. Horizon Databook has segmented the Brazil pharmaceutical market based on biologics & biosimilars (large molecules), conventional drugs (small molecules) covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil is the largest and highest-value pharmaceutical market in Latin America, with a major focus on generic drugs due to their affordability. The country benefits from universal healthcare coverage through its unified Sistema Único de Saúde (SUS), which provides treatments and services at no cost to the population.
With nearly 7,500 medical facilities—more than any other Latin American country—Brazil’s healthcare infrastructure supports a rapidly growing demand for pharmaceuticals. Additionally, 23% of the population has private healthcare insurance, further expanding access to medical services. Brazil's pharmaceutical market offers lucrative opportunities, particularly for international companies.
These companies are increasingly investing in the country due to the higher return on investment available in emerging markets like Brazil, compared to developed markets. This investment is also fueled by Brazil's growing pharmaceutical demand, particularly driven by an aging population and the rising incidence of non-communicable diseases (NCDs) like hypertension, oncology, and obesity—21.5% of Brazilians are obese and highly susceptible to NCDs.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil pharmaceutical market , including forecasts for subscribers. This country databook contains high-level insights into Brazil pharmaceutical market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related industry reports found.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account